Amneal Pharmaceuticals Q2 Results: EPS beats estimate by 36%

1 min read | Published on 30 Jul 2026, 03:54 PM |Updated on 30 Jul 2026, 03:54 PM

Reviewed by

Shriram SScanX News Team

Key Highlights

Amneal Pharmaceuticals posted Q2 EPS of $0.30, beating the $0.22 estimate by 36.36% and rising 20% YoY. Sales hit $796.197M, beating the $768.206M estimate and growing 9.82% from $725.000M last year.

*this image is generated using AI for illustrative purposes only.

Amneal Pharmaceuticals (NASDAQ: AMRX) delivered a strong second-quarter performance, reporting earnings per share (EPS) of $0.30, which significantly beat the analyst consensus estimate of $0.22 by 36.36 percent. This result marks a 20 percent increase over the $0.25 per share earned in the same period last year. The company also reported quarterly sales of $796.197 million, surpassing the $768.206 million estimate by 3.64 percent and reflecting a 9.82 percent year-over-year growth from sales of $725.000 million in the prior year.

The results highlight robust top-line growth alongside a substantial improvement in profitability metrics. While revenue expanded by nearly 10 percent compared to the previous year, earnings grew at a faster pace, indicating improved operational efficiency or margin expansion during the quarter.

Financial Performance Highlights

The following table summarizes Amneal Pharmaceuticals' key financial metrics for the quarter:

Metric	Reported Value	Estimate	Beat/Miss	YoY Change
EPS ($)	0.30	0.22	+36.36%	+20%
Sales ($M)	796.197	768.206	+3.64%	+9.82%

What the Numbers Show

The divergence between the EPS beat of 36.36 percent and the more modest sales beat of 3.64 percent suggests that Amneal Pharmaceuticals benefited from factors beyond mere volume growth. With earnings rising 20 percent year-over-year while sales increased by 9.82 percent, the company appears to have leveraged its scale to improve net margins. This outperformance in profitability relative to revenue growth is a positive signal for investors, indicating effective cost management or favorable product mix dynamics during the quarter.

What specific operational efficiencies or cost-saving measures drove the significant margin expansion beyond revenue growth?

How will this strong Q2 performance influence Amneal's full-year guidance and analyst target prices for AMRX?

Which specific product lines or therapeutic areas contributed most to the 9.82% year-over-year sales increase?

Amneal expands iohexol portfolio with FDA approval of new strengths

1 min read | Published on 17 Jul 2026, 06:14 PM |Updated on 17 Jul 2026, 06:15 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Amneal Pharmaceuticals, Inc. secured FDA approval for iohexol injection 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, and 300 mg iodine/mL in 50 mL vials. The company plans to launch these products in Q3FY26 to address the majority of U.S. market demand, supported by IQVIA data showing annual sales of approximately $706 million for the 12 months ended May 2026.

*this image is generated using AI for illustrative purposes only.

Amneal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, significantly expanding its injectable contrast portfolio. The approval includes 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vials. Amneal plans to launch these products in the third quarter of 2026, positioning the portfolio to address the majority of U.S. market demand for iohexol injection.

Iohexol is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients two weeks of age and older. The newly approved presentations complement Amneal’s previously approved and launched iohexol injection 300 mg iodine/mL in 100 mL vials. These approvals represent the first generic versions referencing OMNIPAQUE™ across the approved presentations.

Market Impact

With approvals spanning multiple strengths and vial presentations, Amneal expects its iohexol portfolio to address the majority of U.S. market demand for iohexol injection. This provides hospitals, imaging centers, and healthcare providers with greater flexibility and supply optionality.

Financial Context

According to IQVIA®, U.S. annual sales for iohexol injection for the 12 months ended May 2026 were approximately $706 million. This market size underscores the significance of Amneal’s expanded portfolio in the complex injectables and hospital products segment.